Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Smith & Nephew Snats ( (SNN) ) has provided an announcement.
On 23 March 2026, Smith & Nephew plc reported the vesting of 2023 performance share awards under its Global Share Plans 2020 and 2010, with senior executives including CEO Deepak Nath receiving ordinary shares and selling portions to meet tax obligations. The company also disclosed the vesting of deferred bonus share awards and partial vesting of 2025 restricted share awards under the 2024 Restricted Share Plan, resulting in further share sales for tax, underscoring the continuing use of stock-based remuneration to incentivise management while modestly increasing leadership equity exposure without signaling any change in strategic direction.
These transactions, notified on 24 March 2026 in line with UK Market Abuse Regulation, involve persons discharging managerial responsibilities and are conducted on the London Stock Exchange at a reference price of £11.938637 per share. While primarily administrative in nature, the disclosures provide transparency for investors about insider holdings and reinforce regulatory compliance around executive compensation structures at the FTSE-listed medtech group.
The most recent analyst rating on (SNN) stock is a Buy with a $41.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.
The score is driven primarily by improving financial performance (margin and cash flow rebound) and supportive technicals (price above major moving averages with positive momentum). Valuation is only average at a 22.7 P/E, while the earnings call adds confidence via upbeat 2026 growth/profit guidance but flags meaningful near-term tariff and reimbursement headwinds.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith & Nephew plc is a UK-based medical technology company focused on orthopaedics, sports medicine, and advanced wound management. Listed on the London Stock Exchange, it uses equity-based incentive schemes to align senior leadership and key managers with long-term shareholder value and company performance.
Average Trading Volume: 886,930
Technical Sentiment Signal: Buy
Current Market Cap: $13.5B
For a thorough assessment of SNN stock, go to TipRanks’ Stock Analysis page.